Bayer Other Operating Income or Expenses 2012-2025 | BAYRY

Bayer annual/quarterly other operating income or expenses history and growth rate from 2012 to 2025. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
  • Bayer other operating income or expenses for the quarter ending December 31, 2025 were $-4.929B, a 280.41% decline year-over-year.
  • Bayer other operating income or expenses for the twelve months ending December 31, 2025 were $-8.346B, a 136.6% increase year-over-year.
  • Bayer annual other operating income or expenses for 2025 were $-8.346B, a 136.6% increase from 2024.
  • Bayer annual other operating income or expenses for 2024 were $-3.528B, a 53.24% decline from 2023.
  • Bayer annual other operating income or expenses for 2023 were $-7.544B, a 1877.86% increase from 2022.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Bayer Annual Other Operating Income or Expenses
(Millions of US $)
2025 $-8,346
2024 $-3,528
2023 $-7,544
2022 $-381
2021 $-3,756
2020 $-17,561
2019 $-429
2018 $2,436
2017 $-95
2016 $-40
2015 $-189
2014 $-178
2013 $-960
2012 $-2,411
2011
Bayer Quarterly Other Operating Income or Expenses
(Millions of US $)
2025-12-31 $-4,929
2025-09-30 $-1,161
2025-06-30 $-1,599
2025-03-31 $-657
2024-12-31 $2,732
2024-09-30 $-3,756
2024-06-30 $-2,551
2024-03-31 $48
2023-12-31 $-523
2023-09-30 $-4,373
2023-06-30 $-2,583
2023-03-31 $-64
2022-12-31 $240
2022-09-30 $-181
2022-06-30 $-607
2022-03-31 $166
2021-12-31 $-63
2021-09-30 $-40
2021-06-30 $-3,861
2021-03-31 $207
2020-12-31 $-473
2020-09-30 $-3,292
2020-06-30 $-13,188
2020-03-31 $-608
2019-12-31 $-1
2019-09-30 $260
2019-06-30 $-407
2019-03-31 $-282
2018-12-31 $-2,510
2018-09-30 $4,690
2018-06-30 $186
2018-03-31 $70
2017-12-31 $-167
2017-09-30 $42
2017-06-30 $27
2017-03-31 $2
2016-12-31 $-112
2016-09-30 $30
2016-06-30 $41
2016-03-31 $1
2015-12-31 $178
2015-09-30 $-42
2015-06-30 $-201
2015-03-31 $-123
2014-12-31 $-345
2014-09-30 $89
2014-06-30 $29
2014-03-31 $49
2013-12-31 $-525
2013-09-30 $-44
2013-06-30 $-303
2013-03-31 $-89
2012-12-31 $-453
2012-09-30 $-566
2012-06-30 $-1,095
2012-03-31 $-298
2011-12-31
2011-09-30
2011-06-30
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $46.178B $51.552B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $887.629B 38.81
Johnson & Johnson (JNJ) United States $574.358B 22.08
AbbVie (ABBV) United States $367.673B 20.79
Roche Holding AG (RHHBY) Switzerland $318.782B 0.00
Merck (MRK) United States $299.893B 13.54
Novartis AG (NVS) Switzerland $293.951B 17.16
Novo Nordisk (NVO) Denmark $167.527B 9.60
Pfizer (PFE) United States $153.074B 8.33
Sanofi (SNY) France $114.048B 10.56
Innoviva (INVA) United States $1.760B 5.88